Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 5:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Immune Markers Clear all
Completed Not applicable Interventional

Effectiveness of Adding Interleukin-2 to Anti-HIV Drugs in Patients Recently Infected With HIV

NCT00006441
View directory record Official record
Conditions
HIV Infections
Interventions
Lamivudine/Zidovudine, Nelfinavir mesylate, Aldesleukin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
2
States / cities
Birmingham, Alabama • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 8, 2015 · Synced Sep 17, 2026, 5:14 AM EDT
Completed Phase 1 Interventional

A Randomized Double Blind Placebo Controlled Study of the Effect of Swallowed Beclomethasone Dipropionate on Inflammatory Markers in Adult Patients With Eosinophilic Esophagitis

NCT01016223
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Beclomethasone dipropionate, placebo
Drug
Lead sponsor
Penn State University
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 29, 2012 · Synced Sep 17, 2026, 5:14 AM EDT
Completed Not applicable Interventional Results available

The Effect of N-Acetyl-L-Cysteine, on Inflammatory and Oxidative Stress Markers in Pulmonary Sarcoidosis

NCT01587001
View directory record Official record
Conditions
Pulmonary Sarcoidosis
Interventions
N-acetyl-cysteine, Placebo
Dietary Supplement · Drug
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years to 80 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 3, 2020 · Synced Sep 17, 2026, 5:14 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Novel Immune Markers in Patients With Multiple Sclerosis

NCT01026272
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
University of Washington
Other
Eligibility
21 Years to 50 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 12, 2010 · Synced Sep 17, 2026, 5:14 AM EDT
Completed No phase listed Observational

Novel Imaging Markers for Rheumatoid Arthritis

NCT01773681
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Cimzia, Magnetic Resonance Imaging (MRI), High-resolution peripheral quantitative computed tomography (HR-pQCT)
Drug · Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 29, 2018 · Synced Sep 17, 2026, 5:14 AM EDT
Completed Phase 4 Interventional Results available

Efficacy of Omalizumab in Adults (18-60 Years of Age) With Moderate-Severe, Persistent Allergic Asthma, Despite Receiving Inhaled Corticosteroids and Long Acting Beta-agonists

NCT00670930
View directory record Official record
Conditions
Allergic Asthma
Interventions
omalizumab at a dose of 0.016mg/kg/IU/mL, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
6
States / cities
Denver, Colorado • St Louis, Missouri • Durham, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2013 · Synced Sep 17, 2026, 5:14 AM EDT
Completed Not applicable Interventional

Gluten Immunity and Islet Autoimmunity in Type-1 Diabetes

NCT01932476
View directory record Official record
Conditions
Type 1 Diabetes, Celiac Disease
Interventions
Gluten Challenge, Sham Challenge
Dietary Supplement
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
18 Years to 50 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 16, 2017 · Synced Sep 17, 2026, 5:14 AM EDT
Completed No phase listed Observational

Periodontal Treatment Response in Type II Diabetic Patients

NCT01881074
View directory record Official record
Conditions
Type II Diabetes, Periodontal Disease
Interventions
Triclosan containing toothpaste, Non-triclosan containing toothpaste
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 70 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 16, 2018 · Synced Sep 17, 2026, 5:14 AM EDT
Completed Phase 3 Interventional

Vitamin D for Enhancing the Immune System in Cystic Fibrosis (DISC Study)

NCT01426256
View directory record Official record
Conditions
Cystic Fibrosis, Respiratory Tract Infections
Interventions
Cholecalciferol
Dietary Supplement
Lead sponsor
Emory University
Other
Eligibility
16 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
5
States / cities
Birmingham, Alabama • Atlanta, Georgia • Iowa City, Iowa + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2017 · Synced Sep 17, 2026, 5:14 AM EDT
Completed Phase 4 Interventional

Mometasone and Markers of Airway Inflammation

NCT00711165
View directory record Official record
Conditions
Asthma
Interventions
Placebo, Mometasone Furoate
Drug
Lead sponsor
Creighton University
Other
Eligibility
19 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jul 7, 2008 · Synced Sep 17, 2026, 5:14 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Genetics and Markers of Degenerative and Inflammatory Eye Diseases

NCT00647439
View directory record Official record
Conditions
Diabetic Retinopathy, Age-Related Macular Degeneration (AMD), Uveitis
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
4 Years and older
Enrollment
609 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 9, 2018 · Synced Sep 17, 2026, 5:14 AM EDT
Completed Not applicable Interventional

The Effects of Vitamin D on Glycemic Control and Proinflammatory Markers in Adolescents With T1DM

NCT01697228
View directory record Official record
Conditions
Type 1 Diabetes, Vitamin D Deficiency/Insufficiency
Interventions
Vitamin D
Dietary Supplement
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
13 Years to 21 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 7, 2017 · Synced Sep 17, 2026, 5:14 AM EDT
Completed No phase listed Observational

Pericardial Fat and Inflammation in HIV Patients and Controls

NCT02399384
View directory record Official record
Conditions
Coronary Artery Disease, Human Immunodeficiency Virus (HIV)
Interventions
Not listed
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced Sep 17, 2026, 5:14 AM EDT
Completed Phase 2 Interventional Results available

Effect of Isotretinoin on Immune Activation Among HIV-1 Infected Subjects With Incomplete CD4+ T Cell Recovery

NCT01969058
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Isotretinoin
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years to 80 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
14
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2024 · Synced Sep 17, 2026, 5:14 AM EDT
Completed Phase 1Phase 2 Interventional

Statins and Lupus: Effects of Statins on Clinical Lupus Parameters, Serological Markers and Toll-like Receptors

NCT00519363
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
atorvastatin
Drug
Lead sponsor
The Center for Rheumatic Disease, Allergy, & Immunology
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 23, 2010 · Synced Sep 17, 2026, 5:14 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Phosphatidylethanol and Other Ethanol Consumption Markers

NCT06747364
View directory record Official record
Conditions
Healthy Volunteer, Alcohol Consumption
Interventions
Alcohol (Ethanol)
Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
21 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
2
States / cities
Denton, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 12, 2025 · Synced Sep 17, 2026, 5:14 AM EDT
Completed Phase 3 Interventional Results available

Liraglutide in Adolescents With Type 1 Diabetes

NCT02516657
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Liraglutide
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
15 Years to 21 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2023
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Apr 19, 2025 · Synced Sep 17, 2026, 5:14 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Pollutant Altered Allergic Responses

NCT00011440
View directory record Official record
Conditions
Allergic Rhinitis, Allergy
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1998 – 2002
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 22, 2006 · Synced Sep 17, 2026, 5:14 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Effects of PS-IPC Supplementation on Muscle Mass and Functional Outcomes in Older Adults

NCT00926250
View directory record Official record
Conditions
Immune Senescence, Sarcopenia
Interventions
Oral PS-IPC supplement, Placebo supplement
Dietary Supplement
Lead sponsor
University of Arkansas
Other
Eligibility
60 Years to 85 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jan 17, 2012 · Synced Sep 17, 2026, 5:14 AM EDT
Completed No phase listed Observational

Analysis of Molecular Markers of Drug Resistance in Tumor Biopsies From Previously Untreated Aggressive Non-Hodgkin's Lymphoma

NCT00026910
View directory record Official record
Conditions
Non-Hodgkin Lymphoma
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 17, 2026, 5:14 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Low-moderate Intensity Pedaling During Immunotherapy Administration

NCT04127318
View directory record Official record
Conditions
Cancer of Skin, Cancer of Kidney, Cancer of Bladder, Exercise, Aerobic, Immunotherapy
Interventions
Pedaling Group
Behavioral
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 22, 2022 · Synced Sep 17, 2026, 5:14 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Ketosis-Prone Diabetes Mellitus (KPDM): Metformin Versus Sitagliptin Treatment

NCT01099618
View directory record Official record
Conditions
Ketosis Prone Diabetes, Diabetes Ketoacidosis, Hyperglycemia
Interventions
metformin, placebo, Sitagliptin
Drug
Lead sponsor
Dawn Smiley MD
Other
Eligibility
19 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 17, 2015 · Synced Sep 17, 2026, 5:14 AM EDT
Completed Phase 2 Interventional Results available

Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers

NCT02706717
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Visbiome Extra Strength, Placebo
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
24
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2020 · Synced Sep 17, 2026, 5:14 AM EDT
Recruiting Phase 2 Interventional

The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis

NCT04372615
View directory record Official record
Conditions
Autoimmune Encephalitis, Encephalitis
Interventions
Inebilizumab, Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
12 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
35
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2025 · Synced Sep 17, 2026, 5:14 AM EDT